Login / Signup

Barriers in Access to Idarucizumab in Ischemic Stroke in a Middle-Income Country.

Julián Alejandro RivillasNatalia Llanos-LeytonEder Moreno-VargasHernán BayonaEugenia JaramilloDaniel KafuryPablo Amaya
Published in: The Neurohospitalist (2023)
There are multiple barriers to access idarucizumab in Colombia. The main factors identified are the low medication availability in provincial hospitals and the low medical knowledge. However clinical results in this limited group are satisfactory. Stronger public policies are needed to guarantee optimal stroke treatment in patients on DOACs in Colombia.
Keyphrases
  • healthcare
  • atrial fibrillation
  • mental health
  • public health
  • direct oral anticoagulants
  • adverse drug
  • emergency department